Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Respuestas clínicas Cochrane

Topics

Temas

Study flow diagram

Figuras y tablas -
Figure 1

Study flow diagram

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias summary: review authors' judgements about each risk of bias item for each included study

Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study

Ir a la figura de la revisiónAbrir en una pestaña nueva

Forest plot of comparison: occurrence of CIN2+ at different lengths of follow‐up

Figuras y tablas -
Figure 3

Forest plot of comparison: occurrence of CIN2+ at different lengths of follow‐up

Ir a la figura de la revisiónAbrir en una pestaña nueva

Forest plot of comparison: occurence of CIN3+ at different lengths of follow‐up

Figuras y tablas -
Figure 4

Forest plot of comparison: occurence of CIN3+ at different lengths of follow‐up

Ir a la figura de la revisiónAbrir en una pestaña nueva

Forest plot of comparison: occurence of CIN2 at different lengths of follow‐up

Figuras y tablas -
Figure 5

Forest plot of comparison: occurence of CIN2 at different lengths of follow‐up

Ir a la figura de la revisiónAbrir en una pestaña nueva

Forest plot of comparison: default rates at different lengths of follow‐up

Figuras y tablas -
Figure 6

Forest plot of comparison: default rates at different lengths of follow‐up

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1: Occurence of CIN2+ at different lengths of follow‐up: immediate colposcopy versus cytological surveillance, Outcome 1: Occurrence of CIN2+

Figuras y tablas -
Analysis 1.1

Comparison 1: Occurence of CIN2+ at different lengths of follow‐up: immediate colposcopy versus cytological surveillance, Outcome 1: Occurrence of CIN2+

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2: Occurence of CIN3+ at different lengths of follow‐up: immediate colposcopy versus cytological surveillance, Outcome 1: Occurrence of CIN3+

Figuras y tablas -
Analysis 2.1

Comparison 2: Occurence of CIN3+ at different lengths of follow‐up: immediate colposcopy versus cytological surveillance, Outcome 1: Occurrence of CIN3+

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3: Histology at 12 months: immediate colposcopy versus cytological surveillance, Outcome 1: Presence of any CIN in histology at 12 months

Figuras y tablas -
Analysis 3.1

Comparison 3: Histology at 12 months: immediate colposcopy versus cytological surveillance, Outcome 1: Presence of any CIN in histology at 12 months

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3: Histology at 12 months: immediate colposcopy versus cytological surveillance, Outcome 2: Presence of CIN1/2 in histology at 12 months

Figuras y tablas -
Analysis 3.2

Comparison 3: Histology at 12 months: immediate colposcopy versus cytological surveillance, Outcome 2: Presence of CIN1/2 in histology at 12 months

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3: Histology at 12 months: immediate colposcopy versus cytological surveillance, Outcome 3: Presence of CIN3+ in histology at 12 months

Figuras y tablas -
Analysis 3.3

Comparison 3: Histology at 12 months: immediate colposcopy versus cytological surveillance, Outcome 3: Presence of CIN3+ in histology at 12 months

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4: Histology at 24 months: immediate colposcopy versus cytological surveillance, Outcome 1: Histology at 24 months

Figuras y tablas -
Analysis 4.1

Comparison 4: Histology at 24 months: immediate colposcopy versus cytological surveillance, Outcome 1: Histology at 24 months

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5: Occurence of CIN2 at different lengths of follow‐up: Immediate colposcopy versus cytological surveillance, Outcome 1: Occurrence of CIN2

Figuras y tablas -
Analysis 5.1

Comparison 5: Occurence of CIN2 at different lengths of follow‐up: Immediate colposcopy versus cytological surveillance, Outcome 1: Occurrence of CIN2

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6: Default rates: immediate colposcopy versus cytological surveillance, Outcome 1: Default rates

Figuras y tablas -
Analysis 6.1

Comparison 6: Default rates: immediate colposcopy versus cytological surveillance, Outcome 1: Default rates

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7: Histology at 24 months: immediate colposcopy versus cytological surveillance, LSIL/mild dyskaryosis only, Outcome 1: CIN incidence at 24 months, after LSIL/mild dyskaryosis at baseline

Figuras y tablas -
Analysis 7.1

Comparison 7: Histology at 24 months: immediate colposcopy versus cytological surveillance, LSIL/mild dyskaryosis only, Outcome 1: CIN incidence at 24 months, after LSIL/mild dyskaryosis at baseline

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8: Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1 trial, Outcome 1: Presence of CIN2 in histology at 24 months

Figuras y tablas -
Analysis 8.1

Comparison 8: Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1 trial, Outcome 1: Presence of CIN2 in histology at 24 months

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8: Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1 trial, Outcome 2: Presence of CIN2+ in histology at 24 months

Figuras y tablas -
Analysis 8.2

Comparison 8: Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1 trial, Outcome 2: Presence of CIN2+ in histology at 24 months

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8: Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1 trial, Outcome 3: Presence of CIN3+ in histology at 24 months

Figuras y tablas -
Analysis 8.3

Comparison 8: Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1 trial, Outcome 3: Presence of CIN3+ in histology at 24 months

Ir a la figura de la revisiónAbrir en una pestaña nueva
Summary of findings 1. Summary of findings: occurrence of CIN and default rates

Immediate colposcopy compared with cytological surveillance for minor cervical cytological abnormalities: occurrence of different grades CIN in histology according to follow‐up time and default rates

Patient or population: women with ASCUS or LSIL

Settings: colposcopy clinic

Intervention: immediate colposcopy

Comparison: cytological surveillance

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Risk with cytological surveillance

Risk with immediate colposcopy

Occurrence of CIN2+ in histology at 18 months

101 per 1000

151 per 1000
(113 to 203)

RR 1.50 (1.12 to 2.01)

4028
(2 studies)

⊕⊕⊕⊝
moderate1

Occurrence of CIN2+ in histology at 24 months

183 per 1000

209 per 1000
(121 to 361)

RR 1.14 (0.66 to 1.97)

4331
(3 studies)

⊕⊕⊝⊝
low2,3

Occurrence of CIN3+ in histology at 18 months

69 per 1000

86 per 1000
(53 to 137)

RR 1.24 (0.77 to 1.98)

4028
(2 studies)

⊕⊕⊕⊝
moderate4

Occurrence of CIN3+ in histology at 24 months

119 per 1000

121 per 1000
(63 to 234)

RR 1.02 (0.53 to 1.97)

4331
(3 studies)

⊕⊕⊝⊝
low3,5

Occurrence of any CIN in histology at 24 months

316 per 1000

639 per 1000
(420 to 974)

RR 2.02 (1.33 to 3.08)

656
(2 studies)

⊕⊕⊝⊝
low3,8

Default rates at 6 months

63 per 1000

241 per 1000
(80 to 728)

RR 3.85
(1.27 to 11.63)

5117
(3 study)

⊕⊕⊕⊝

moderate6

Default rates at 12 months

63 per 1000

413 per 1000
(93 to 1000)

RR 6.60
(1.49 to 29.29

5115
(3 studies)

⊕⊕⊕⊝

moderate7

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). For default rates the relative effect is calculated between cytological surveillance versus immediate colposcopy. For histology the relative effect is calculated between immediate colposcopy versus cytological surveillance.
ASCUS: atypical squamous cells of undetermined significance CI: Confidence interval; CIN: cervical intraepithelial neoplasia; LSIL: low‐grade squamous intra‐epithelial lesions; RR: Risk Ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Downgraded to moderate due to substantial inter‐study heterogeneity (P = 0.08, I2= 61%).
2 Downgraded to low due to considerable inter‐study heterogeneity (P < 0.00001, I2= 94%).
3 Downgraded due to presence of the other possible bias resulting in falsely high CIN detection rate in the cytological surveillance arm.
4 Downgraded to moderate due to substantial inter‐study heterogeneity (P = 0.02, I2= 75%).
5 Downgraded to low due to considerable inter‐study heterogeneity (P < 0.00001, I2= 93%).
6 Downgraded to moderate due to considerable inter‐study heterogeneity (P = 0.02, I2= 76%).
7 Downgraded to moderate due to considerable inter‐study heterogeneity (P = 0.0004, I2= 87%).
8 Downgraded to low due to substantial inter‐study heterogeneity (P = 0.02, I2 = 82%).

Figuras y tablas -
Summary of findings 1. Summary of findings: occurrence of CIN and default rates
Ir a la tabla de la revisión
Table 1. Reported individual outcomes in the included studies

Study

Outcomes

Immediate colposcopy

n/N (%)

Cytological surveillance

n/N (%)

RR + 95% CI

ALTS 2003(ASCUS)

Histology at 18 monthsa

CIN 2

61/1163 (5.2)

26/1164 (2.2)

2.35 [1.49, 3.69]

CIN 2+

119/1163 (10.2)

92/1164 (7.9)

1.29 [1.00, 1.68]

CIN 3+

58/1163 (5.0)

66/1164 (5.7)

0.88 [0.62, 1.24]

Histology at 24 months

CIN 2

61/1163 (5.2)

60/1164 (5.2)

1.02 [0.72,1.44]

CIN 2+

119/1163 (10.2)

168/1164 (14.4)

0.71 [0.57, 0.88]

CIN 3+

58/1163 (5.0)

108/1164 (9.3)

0.54 [0.39, 0.73]

Default rates:

Default rate at 24 months

15/1163 (1.3)

165/1164 (14.2)

10.99 [6.52, 18.53]

ALTS 2003(LSIL)

Histology at 18 monthsa

CIN 2

63/673 (9.4)

36/675 (5.3)

1.76 [1.18, 2.61]

CIN 2+

127/673 (18.9)

95/675 (14.1)

1.34 [1.05, 1.71]

CIN 3+

64/673 (9.5)

59/675 (8.7)

1.09 [0.78, 1.52]

Histology at 24 months

CIN 2

63/673 (9.4)

58/675 (8.6)

1.09 [0.78,1.53]

CIN 2+

127/673 (18.9)

151/675 (22.4)

0.84 [0.68, 1.04]

CIN 3+

64/673 (9.5)

93/675 (13.8)

0.69 [0.51, 0.93]

Default rates:

Default rate at 24 months

4/673 (0.6)

110/675 (16.3)

27.42 [10.17, 73.93]

Flannelly 1994

Histology at 6 months

HPV / Koilocytic atypia

13/145 (9.0)

28/160 (17.5)

0.52 [0.28, 0.95]

Any CIN

121/145 (83.4)

86/160 (53.8)

1.55 [1.32, 1.82]

CIN 1

23/145 (15.9)

27/160 (16.9)

0.94 [0.57, 1.56]

CIN 2

32/145 (22.1)

26/160 (16.3)

1.36 [0.85, 2.16]

CIN 2+

98/145 (67.6)

59/160 (36.9)

1.83 [1.45, 2.31]

CIN 3+

66/145 (45.5)

33/160 (20.6)

2.21 [1.55, 3.14]

Histology at 12 months

HPV / Koilocytic atypia

13/145 (9.0)

18/158 (11.4)

0.79 [0.40, 1.55]

Any CIN

121/145 (83.4)

96/158 (60.8)

1.37 [1.19, 1.59]

CIN 1

23/145 (15.9)

25/158 (15.8)

1.00 [0.60, 1.69]

CIN 2

32/145 (22.1)

26/158 (16.5)

1.34 [0.84, 2.14]

CIN 1 / 2

55/145 (37.9)

51/158 (32.3)

1.18 [0.86, 1.60]

CIN 2+

98/145 (67.6)

71/158 (44.9)

1.50 [1.22, 1.85]

CIN 3+

66/145 (45.5)

45/158 (28.5)

1.60 [1.18, 2.17]

Histology at 24 months

HPV / Koilocytic atypia

13/145 (9.0)

11/158 (7.0)

1.29 [0.60, 2.78]

Any CIN

121/145 (83.4)

53/158 (33.5)

2.49 [1.97, 3.13]

CIN 1

23/145 (15.9)

9/158 (5.7)

2.78 [1.33, 5.82]

CIN 2

32/145 (22.1)

12/158 (7.6)

2.91 [1.56, 5.42]

CIN 2+

98/145 (67.6)

44/158 (27.8)

2.43 [1.84, 3.20]

CIN 3+

66/145 (45.5)

32/158 (20.3)

2.25 [1.57, 3.21]

Default rates:

Default rate at 6 months

0/145 (0)

19/160 (11.9)

35.37 [2.15, 580.52]

Default rate at 12 months

0/145 (0)

23/158 (14.6)

43.16 [2.65, 704.13]

Default rate at 24 months

0/145 (0)

38/158 (24.1)

70.70 [4.38, 1140.47]

Kitchener 2004

Histology at 12 months

Any CIN

83/130 (63.8)

71/243 (29.2)

2.19 [1.73, 2.76]

CIN 1 / 2

61/130 (46.9)

47/243 (19.3)

2.43 [1.77, 3.32]

CIN 3+

22/130 (16.9)

24/243 (9.9)

1.71 [1.00, 2.93]

Default rates:

Default rate at 6 months

5/130 (3.8)

46/243 (18.9)

4.92 [2.01, 12.08]

Default rate at 12 months

5/130 (3.8)

95/243 (39.1)

10.16 [4.24, 24.35]

GHQ casenessb

Choicec

No choicec

Baseline

134/233 (58)

119/241 (49)

1.16 [0.98, 1.38]

6 months (pre visit)

71/183 (39)

77/190 (41)

0.96 [0.75, 1.23]

6 months (post visit)

59/175 (34)

66/177 (37)

0.90 [0.68, 1.20]

12 months

40/135 (29)

35/127 (28)

1.08 [0.73, 1.58]

Shafi 1997

Histology at 18 monthsa

CIN 2

8/182(4.4)

2/171 (1.1)

3.76 [0.81, 17.45]

CIN 2+

43/182 (23.6)

16/171 (9.4)

2.53 [1.48, 4.31]

CIN 3+

35/182 (19.2)

14/171(8.2)

2.35 [1.31, 2.45]

Histology at 24 months

HPV / Koilocytic atypia

92/182 (50.5)

57/171 (33.3)

1.52 [1.17, 1.96]

Any CIN

88/182 (48.4)

51/171 (29.8)

1.62 [1.23, 2.13]

CIN 1

45/182 (24.7)

17/171 (9.9)

2.49 [1.48, 4.17]

CIN 2

8/182 (4.4)

10/171 (5.8)

0.75 [0.30, 1.86]

CIN 2+

43/182 (23.6)

34/171 (19.9)

1.19 [0.80, 1.77]

CIN 3+

35/182 (19.2)

24/171 (14.0)

1.37 [0.85, 2.20]

Default rates:

Default rate at 24 months

1/182 (0.5)

36/171 (21.1)

38.32 [5.31, 276.40]

Tombola 2009

Histology at 30 monthsa

CIN 2

181/2216 (8.2)

101/2223 (4.5)

1.80 [1.42, 2.28]

CIN 2+

369/2216 (16.7)

269/2223 (12.1)

1.38 [1.19, 1.59]

CIN 3+

188/2216 (8.5)

168/2223 (7.6)

1.12 [0.92, 1.37]

Histology at 36 months

CIN 2

181/2216 (8.2)

157/2223 (7.1)

1.16 [0.94, 1.42]

CIN 2+

369/2216 (16.7)

350/2223 (15.7)

1.06 [0.93, 1.21]

CIN 3+

188/2216 (8.5)

193/2223 (8.7)

0.98 [0.81, 1.18]

Default rates:

Default rate at 6 months

151/2216 (6.8)

285/2223 (12.8)

1.88 [1.56, 2.27]

Default rate at 12 months

151/2216 (6.8)

327/2223 (14.7)

2.16 [1.80, 2.59]

Paind

Any pain

304/782 (38.9)

145/968 (15.0)

2.60 [2.18, 3.09]

Moderate or more severe

144/774 (18.6)

56/965 (5.8)

3.21 [2.39, 4.30]

Bleedingd

Any bleeding

366/781 (46.9)

166/967 (17.2)

2.73 [2.33, 3.19]

Moderate or more severe

144/772 (18.6)

16/961 (1.7)

11.20 [6.74, 18.61]

Discharged

Any discharge

267/780 (34.2)

83/964 (8.6)

3.98 [3.17, 4.99]

Moderate or more severe

133/777 (17.1)

36/962 (3.7)

4.57 [3.20, 6.53]

Anxietye

6 weeks

59/751 (7.9)

121/900 (13.4)

0.58 [0.43, 0.79]

12 months

190/1161 (16.4)

218/1130 (19.3)

0.85 [0.71, 1.01]

18 months

162/1050 (15.4)

177/1008 (17.6)

0.88 [0.72, 1.07]

24 months

179/1001 (17.9)

177/962 (18.4)

0.97 [0.81, 1.17]

30 months

146/949 (15.4)

143/887 (16.1)

0.95 [0.77, 1.18]

Depressionf

6 weeks

50/757 (6.6)

68/902 (7.5)

0.88 [0.62, 1.25]

12 months

110/1162 (9.5)

132/1136 (11.6)

0.81 [0.64, 1.04]

18 months

106/1052 (10.1)

114/1016 (11.2)

0.90 [0.70, 1.15]

24 months

111/1001 (11.1)

104/964 (10.8)

1.03 [0.80, 1.32]

30 months

101/948 (10.7)

108/887 (12.2)

0.88 [0.68, 1.13]

For Immediate colposcopy, n = n at immediate colposcopy visit, possible follow‐up excluded.

a Cumulative incidence during follow‐up, excluding the exit examination or deferred treatment.

b GHQ caseness = GHQ (General Health Questionnaire) score ≥ 4.

c Analysis for this outcome between the original randomization groups.

d Based on Questionnaire 6 weeks after immediate colposcopy or first cytological surveillance visit.

e ≥ 11 on hospital anxiety and depression anxiety subscale

f ≥ 8 on hospital anxiety and depression subscale

Figuras y tablas -
Table 1. Reported individual outcomes in the included studies
Ir a la tabla de la revisión
Comparison 1. Occurence of CIN2+ at different lengths of follow‐up: immediate colposcopy versus cytological surveillance

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1.1 Occurrence of CIN2+ Show forest plot

3

Risk Ratio (IV, Random, 95% CI)

Subtotals only

1.1.1 18 months' surveillance

2

4028

Risk Ratio (IV, Random, 95% CI)

1.50 [1.12, 2.01]

1.1.2 24 months' surveillance

3

4331

Risk Ratio (IV, Random, 95% CI)

1.14 [0.66, 1.97]
Figuras y tablas -
Comparison 1. Occurence of CIN2+ at different lengths of follow‐up: immediate colposcopy versus cytological surveillance
Ir a la tabla de la revisión
Comparison 2. Occurence of CIN3+ at different lengths of follow‐up: immediate colposcopy versus cytological surveillance

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

2.1 Occurrence of CIN3+ Show forest plot

4

Risk Ratio (IV, Random, 95% CI)

Subtotals only

2.1.1 12 months' surveillance

2

676

Risk Ratio (IV, Random, 95% CI)

2.07 [1.54, 2.79]

2.1.2 18 months' surveillance

2

4028

Risk Ratio (IV, Random, 95% CI)

1.24 [0.77, 1.98]

2.1.3 24 months' surveillance

3

4331

Risk Ratio (IV, Random, 95% CI)

1.02 [0.53, 1.97]
Figuras y tablas -
Comparison 2. Occurence of CIN3+ at different lengths of follow‐up: immediate colposcopy versus cytological surveillance
Ir a la tabla de la revisión
Comparison 3. Histology at 12 months: immediate colposcopy versus cytological surveillance

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

3.1 Presence of any CIN in histology at 12 months Show forest plot

2

676

Risk Ratio (IV, Random, 95% CI)

1.72 [1.09, 2.70]

3.2 Presence of CIN1/2 in histology at 12 months Show forest plot

2

676

Risk Ratio (IV, Random, 95% CI)

1.69 [0.83, 3.43]

3.3 Presence of CIN3+ in histology at 12 months Show forest plot

2

676

Risk Ratio (IV, Random, 95% CI)

1.63 [1.25, 2.12]
Figuras y tablas -
Comparison 3. Histology at 12 months: immediate colposcopy versus cytological surveillance
Ir a la tabla de la revisión
Comparison 4. Histology at 24 months: immediate colposcopy versus cytological surveillance

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

4.1 Histology at 24 months Show forest plot

3

Risk Ratio (IV, Random, 95% CI)

Subtotals only

4.1.1 HPV/Koilocytic atypia

2

656

Risk Ratio (IV, Random, 95% CI)

1.49 [1.17, 1.90]

4.1.2 Any CIN

2

656

Risk Ratio (IV, Random, 95% CI)

2.02 [1.33, 3.08]

4.1.3 CIN1

2

656

Risk Ratio (IV, Random, 95% CI)

2.58 [1.69, 3.94]

4.1.4 CIN2

3

4331

Risk Ratio (IV, Random, 95% CI)

1.25 [0.80, 1.96]

4.1.5 CIN2+

3

4331

Risk Ratio (IV, Random, 95% CI)

1.14 [0.66, 1.97]

4.1.6 CIN3+

3

4331

Risk Ratio (IV, Random, 95% CI)

1.02 [0.53, 1.97]
Figuras y tablas -
Comparison 4. Histology at 24 months: immediate colposcopy versus cytological surveillance
Ir a la tabla de la revisión
Comparison 5. Occurence of CIN2 at different lengths of follow‐up: Immediate colposcopy versus cytological surveillance

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

5.1 Occurrence of CIN2 Show forest plot

3

Risk Ratio (IV, Random, 95% CI)

Subtotals only

5.1.1 18 months' surveillance

2

4028

Risk Ratio (IV, Random, 95% CI)

2.04 [1.52, 2.73]

5.1.2 24 months' surveillance

3

4331

Risk Ratio (IV, Random, 95% CI)

1.45 [0.87, 2.40]
Figuras y tablas -
Comparison 5. Occurence of CIN2 at different lengths of follow‐up: Immediate colposcopy versus cytological surveillance
Ir a la tabla de la revisión
Comparison 6. Default rates: immediate colposcopy versus cytological surveillance

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

6.1 Default rates Show forest plot

5

Risk Ratio (IV, Random, 95% CI)

Subtotals only

6.1.1 Default rates at 6 months

3

5117

Risk Ratio (IV, Random, 95% CI)

3.85 [1.27, 11.63]

6.1.2 Default rates at 12 months

3

5115

Risk Ratio (IV, Random, 95% CI)

6.60 [1.49, 29.29]

6.1.3 Default rates at 24 months

3

4331

Risk Ratio (IV, Random, 95% CI)

19.10 [9.02, 40.43]
Figuras y tablas -
Comparison 6. Default rates: immediate colposcopy versus cytological surveillance
Ir a la tabla de la revisión
Comparison 7. Histology at 24 months: immediate colposcopy versus cytological surveillance, LSIL/mild dyskaryosis only

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

7.1 CIN incidence at 24 months, after LSIL/mild dyskaryosis at baseline Show forest plot

2

Risk Ratio (IV, Random, 95% CI)

Subtotals only

7.1.1 CIN2 incidence at 24 months

2

1651

Risk Ratio (IV, Random, 95% CI)

1.72 [0.66, 4.48]

7.1.2 CIN2+ incidence at 24 months

2

1651

Risk Ratio (IV, Random, 95% CI)

1.43 [0.51, 4.01]

7.1.3 CIN3+ incidence at 24 months

2

1651

Risk Ratio (IV, Random, 95% CI)

1.24 [0.39, 3.94]
Figuras y tablas -
Comparison 7. Histology at 24 months: immediate colposcopy versus cytological surveillance, LSIL/mild dyskaryosis only
Ir a la tabla de la revisión
Comparison 8. Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1 trial

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

8.1 Presence of CIN2 in histology at 24 months Show forest plot

2

656

Risk Ratio (IV, Random, 95% CI)

1.54 [0.41, 5.78]

8.2 Presence of CIN2+ in histology at 24 months Show forest plot

2

656

Risk Ratio (IV, Random, 95% CI)

1.72 [0.86, 3.47]

8.3 Presence of CIN3+ in histology at 24 months Show forest plot

2

656

Risk Ratio (IV, Random, 95% CI)

1.80 [1.11, 2.92]
Figuras y tablas -
Comparison 8. Histology at 24 months: immediate colposcopy versus cytological surveillance, excluding 1 trial
Ir a la tabla de la revisión